Dashboard
Manage Tickers

MRUSMerus N.V.

Nasdaq merus.nl


$ 53.29 $ -4.06 (-7.09 %)    

Friday, 31-May-2024 15:59:53 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -0.84 (-0.19 %)
DIA $ 398.57 $ 6.05 (1.59 %)
SPY $ 530.36 $ 4.76 (0.91 %)
TLT $ 91.26 $ 0.61 (0.68 %)
GLD $ 225.37 $ -1.27 (-0.59 %)
$ 53.24
$ 57.51
$ 0.00 x 0
$ 55.87 x 102
$ 52.89 - $ 57.51
$ 19.81 - $ 61.61
1,717,915
na
3.09B
$ 1.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-16-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

reported-earlier-merus-prices-upsized-public-offering-of-755m-common-shares-at-53share
Reported Earlier, Merus Prices Upsized Pub...
05/30/2024 06:15:18

The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses a...

b-of-a-securities-maintains-buy-on-merus-raises-price-target-to-80
B of A Securities Maintains Buy on Merus, ...
05/29/2024 12:07:16

B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $61 to $80.

hc-wainwright--co-maintains-buy-on-merus-raises-price-target-to-85
HC Wainwright & Co. Maintains Buy on Merus...
05/29/2024 10:26:44

HC Wainwright & Co. analyst Andrew Fein maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $65 to...

merus-announces-300m-proposed-public-offering
Merus Announces $300M Proposed Public Offe...
05/28/2024 20:02:01

why-applied-dna-sciences-shares-are-trading-lower-by-around-68-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Applied DNA Sciences Shares Are Tradin...
05/28/2024 17:24:16

needham-maintains-buy-on-merus-raises-price-target-to-92
Needham Maintains Buy on Merus, Raises Pri...
05/28/2024 16:42:19

Needham analyst Ami Fadia maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $66 to $92.

guggenheim-maintains-buy-on-merus-raises-price-target-to-93
Guggenheim Maintains Buy on Merus, Raises ...
05/28/2024 15:45:33

Guggenheim analyst Michael Schmitz maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $57 to $93.

stifel-maintains-buy-on-merus-raises-price-target-to-90
Stifel Maintains Buy on Merus, Raises Pric...
05/28/2024 14:29:49

Stifel analyst Bradley Canino maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $65 to $90.

merus-reveals-interim-results-for-bispecific-antibody-petosemtamab-with-pembrolizumab-at-2024-american-society-of-clinical-oncology-annual-meeting
Merus Reveals Interim Results for Bispecif...
05/28/2024 11:08:08

 Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-lengt...

crude-oil-rises-1-verastem-shares-slide
Crude Oil Rises 1%; Verastem Shares Slide
05/24/2024 18:47:50

why-netease-shares-are-trading-lower-here-are-other-stocks-moving-in-fridays-mid-day-session
Why NetEase Shares Are Trading Lower? Here...
05/24/2024 17:57:35

why-is-cancer-focused-merus-stock-trading-over-30-on-friday
Why Is Cancer-Focused Merus Stock Trading ...
05/24/2024 17:41:19

Merus announces interim clinical data on petosemtamab and Keytruda (pembrolizumab) for first-line recurrent/metastatic head and...

nasdaq-gains-1-intuit-shares-plunge
Nasdaq Gains 1%; Intuit Shares Plunge
05/24/2024 16:07:54

deckers-outdoor-posts-upbeat-earnings-joins-guardant-health-ross-stores-and-other-big-stocks-moving-higher-on-friday
Deckers Outdoor Posts Upbeat Earnings, Joi...
05/24/2024 14:12:17

Core News & Articles
Market-Moving News for May 24th
05/24/2024 12:46:45

MRUS: 23% | Merus shares are trading higher after the company announced the publication of an abstract regarding petosemtamab i...

reported-earlier-merus-announces-publication-of-an-abstract-on-petosemtamab-with-pembrolizumab-as-1l-treatment-of-rm-hnscc-at-2024-american-society-of-clinical-oncology-annual-meeting
Reported Earlier, Merus Announces Publicat...
05/24/2024 11:38:28

The abstract presents interim clinical data from a cohort of 26 patients enrolled as of the abstract cutoff date, evaluating th...

b-of-a-securities-maintains-buy-on-merus-raises-price-target-to-61
B of A Securities Maintains Buy on Merus, ...
05/24/2024 11:13:24

B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $52 to $61.

hc-wainwright--co-reiterates-buy-on-merus-maintains-65-price-target
HC Wainwright & Co. Reiterates Buy on Meru...
05/24/2024 10:50:21

HC Wainwright & Co. analyst Andrew Fein reiterates Merus (NASDAQ:MRUS) with a Buy and maintains $65 price target.

needham-reiterates-buy-on-merus-maintains-66-price-target
Needham Reiterates Buy on Merus, Maintains...
05/24/2024 10:32:52

Needham analyst Ami Fadia reiterates Merus (NASDAQ:MRUS) with a Buy and maintains $66 price target.

petosemtamab-receives-breakthrough-therapy-designation-from-fda
Petosemtamab Receives Breakthrough Therapy...
05/13/2024 12:23:41

Merus N.V. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pe...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION